StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

Analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued on Tuesday. The firm set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 price target on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Price Performance

BIOL stock opened at $0.01 on Tuesday. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The firm has a 50-day moving average of $0.01 and a 200 day moving average of $0.04. The company has a market cap of $293,981.60, a P/E ratio of 0.00 and a beta of 0.67.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.